KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 36 days ( 3.53 % )
Last Price $0.511 0 %
High/ Low $0.511 - $0.511 0%
Chg 7 Days N/A $0.511 $0.511
Chg 30 Days N/A $0.511 $0.511
Chg 12 mos 3.92 % $0.492 $0.511
Trend - 3 mos 8.27 % Width: 61.06 %
Trend - 12 mos 37.24 % Width: 153.28 %
Pred. range - 3 mos $0.399 - $0.643 -21.92 % - 25.76 %
Pred. range - 12 mos $0.466 - $1.18 -8.82 % - 130.94 %
Short MA avg 3 mos Sell Nov 01, 2023 - 31 days
Long MA avg 3 mos Sell Dec 12, 2023 - 3 days
Short/Long MA avg 3 mos Sell Dec 12, 2023 - 3 days
Short MA avg 12 mos Sell Nov 21, 2023 - 17 days
Long MA avg 12 mos Sell Oct 18, 2023 - 41 days
Short/Long MA avg 12 mos Buy Jun 16, 2023 - 126 days
Pivot Short Buy Oct 30, 2023 - 33 days
Bollinger Sell Nov 30, -1 - N/A days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Catalyst Biosciences

Catalyst Biosciences Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD);... CBIO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT